Chainbase vs Mira — how do they compare? Chainbase trades at Rp1,147 (market cap Rp444,13M, Rp61,22M 24h volume), while Mira trades at Rp705.4 (market cap Rp226,43M, Rp101,47M 24h volume). The key difference: Chainbase is the larger of the two by market cap, and Chainbase's circulating supply is 387M / 1B C (39%) versus 321,5M / 1B MIRA (33%) for Mira. Which is the better fit depends on your goals — on Pluang, investors hold Chainbase for 10 Days and Mira for 22 Days on average.
| C | MIRA | |
|---|---|---|
Market Cap | Rp444,13M | Rp226,43M |
Volume (24h) | Rp61,22M | Rp101,47M |
Circulating Supply | 387M / 1B C (39%) | 321,5M / 1B MIRA (33%) |
Typical Hold Time | 10 Days | 22 Days |
Signals from Pluang's Aura AI — not financial advice
Chainbase is trading at Rp1,118 with a market cap of Rp430.42 million, showing neutral technical signals overall. The token is currently trading near its pivot point of Rp1,122 with bearish moving averages but neutral oscillators. With a 39% circulation rate and average hold time of 10 days, the token shows moderate network activity. Recent technical indicators show RSI levels in neutral territory while ADX signals strong trend momentum.
The outlook remains cautious with the token facing resistance at Rp1,140 while supported at Rp1,095. Key opportunities include potential breakout above resistance levels, while risks involve limited liquidity and typical crypto volatility. Investors should monitor trading volume patterns and network adoption metrics for directional cues.
MIRA token trades at Rp724 with bearish technical signals as moving averages indicate strong selling pressure. The token shows neutral oscillators but faces resistance at Rp726-758 levels. With 33% circulating supply and 22-day average hold time, market participation remains limited. Recent ecosystem developments show progress in pharmaceutical research applications, though direct token utility updates are scarce.
Overall outlook remains cautious due to technical bearishness and limited trading volume. Key opportunity lies in potential protocol adoption from pharmaceutical research partnerships. Major risks include low liquidity, high volatility, and regulatory uncertainty surrounding crypto-pharma intersections. Investors should monitor exchange listings and token utility expansion.
What Pluang investors did over the last 30 days
Chainbase is developing the Hyperdata Network for AI, establishing a foundational layer for the DataFi era. This network converts fragmented on-chain signals into structured, verifiable, and AI-ready data, facilitating seamless collaboration among agents, applications, and humans. Chainbase empowers a decentralized data economy where data is treated as capital—composable, monetizable, and accessible to everyone.
Read more on C →Mira is a decentralized verification network that enables autonomous AI by eliminating human oversight. Using consensus-based verification across multiple AI models, Mira delivers mathematically verifiable and trustless results in real time. This ensures accuracy and reliability for critical fields like healthcare, finance, and law—transforming AI from a supervised tool into truly independent intelligence.
Read more on MIRA →